Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

Rhea-AI Summary

Marinus Pharmaceuticals, Inc. (MRNS) plans to release its financial results for the first quarter ended March 31, 2023, on May 11, 2023. A conference call will follow at 8:30 a.m. Eastern Time on the same day. Investors can access the call via the company's website. Marinus focuses on developing innovative therapeutics for seizure disorders, with its commercial product, ZTALMY® (ganaxolone), approved by the U.S. FDA for treating seizures associated with CDKL5 deficiency disorder in patients aged two and older. The company is also studying ganaxolone in other rare seizure disorders, including its use in Phase 3 trials for tuberous sclerosis complex and refractory status epilepticus. The drug acts as a GABA_A receptor modulator, aiming to enhance treatment for both adult and pediatric patients.

Positive

• Ganaxolone approved for CDKL5 deficiency disorder, expanding market potential.
• Ongoing Phase 3 trials for additional seizure disorders may enhance future revenue.

Negative

• None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023.

Participants may access the conference call via webcast on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005079/en/

Sasha Damouni Ellis

Senior Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

When will Marinus Pharmaceuticals release its first quarter financial results for 2023?

Marinus Pharmaceuticals will release its first quarter financial results on May 11, 2023.

What time is the Marinus Pharmaceuticals conference call scheduled for?

The conference call is scheduled for 8:30 a.m. Eastern Time on May 11, 2023.

What is ZTALMY® and what condition does it treat?

ZTALMY® (ganaxolone) is approved for treating seizures associated with CDKL5 deficiency disorder in patients aged two years and older.

What other conditions are being studied for ganaxolone?

Ganaxolone is being studied in Phase 3 trials for tuberous sclerosis complex and refractory status epilepticus.

How can I access the Marinus Pharmaceuticals conference call?

The conference call can be accessed via webcast on the Investors and Media page of Marinus' website.